glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results CKJ REVIEW agonists in patients with chronic disease and either overweight or obesit 🚨 Journal Club: FLOW Trial

Medical weight loss injections have been associated with improvements in glycemic control, insulin sensitivity, blood pressure, and lipid profile, making them valuable tools for addressing comorbidities commonly associated with obesity, such as type 2 diabetes and cardiovascular disease

This might sound too good to be true, but GLP-1 medicationssuch as Ozempic, Trulicity, and Wegovyare making it a reality for many

Im on week 2 and have lost 4 pounds, and I notice Im not hungry or craving anything

Since GLP-1R is a target in diabetes mellitus, it enhances the proliferation of -cells and insulin secretion in the pancreas and reduces plasma glucose levels [60, 61]